Oxford BioDynamics (LON:OBD) Trading 18.3% Higher – Still a Buy?

Shares of Oxford BioDynamics Plc (LON:OBD) traded up 18.3% on Wednesday . The stock traded as high as GBX 0.20 and last traded at GBX 0.20. 1,739,901 shares were traded during trading, a decline of 88% from the average session volume of 15,004,250 shares. The stock had previously closed at GBX 0.17.

Oxford BioDynamics Trading Up 18.3%

The company has a quick ratio of 2.80, a current ratio of 0.88 and a debt-to-equity ratio of 457.97. The firm’s 50 day simple moving average is GBX 0.20 and its two-hundred day simple moving average is GBX 0.24. The stock has a market cap of £8.58 million, a P/E ratio of -0.25 and a beta of 0.42.

Oxford BioDynamics Company Profile

Oxford BioDynamics Plc is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases.

Its flagship product is EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) for cancer, a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, launched in February 2022.

In March 2021, the Company launched its first commercial prognostic test, EpiSwitch® CST (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch® Explorer Array Kit.